Clinical Trials
703 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
National Institutes of Health Clinical Center (CC)
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
M.D. Anderson Cancer Center
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
M.D. Anderson Cancer Center
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response
University Hospital Dubrava
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
THYSU
University Hospital, Bordeaux
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Studies on Tumors of the Thyroid
National Institutes of Health Clinical Center (CC)
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
Ganoderma Spores Modulate the Gut-Brain Axis
Zhejiang Cancer Hospital
Thyroidectomy-specific Enhanced Recovery After Surgery (ERAS) Protocol
Assiut University
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
IoN
University College, London
PMCAS
Cedars-Sinai Medical Center
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Eastern Cooperative Oncology Group
Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS)
Shanghai 6th People's Hospital
Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy
Shanghai 6th People's Hospital
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
iCaRe2
University of Nebraska
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
National Institutes of Health Clinical Center (CC)
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Taichung Veterans General Hospital
Effect of Exergaming Exercises and Mediterranean Diet on Thyroid Cancer Patients Following Total Thyroidectomy
Cairo University
DP-04
AstraZeneca
NAVIGATE
Bayer
A Study of Optical Imaging With Light From Radiotracers in Cancer Patients
Memorial Sloan Kettering Cancer Center
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
M.D. Anderson Cancer Center
LIBRETTO-321
Eli Lilly and Company
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Oropharynx (OPX) Biomarker Trial
Mayo Clinic
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
University of California, San Francisco
EECRTKI
University of Pisa
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial
Brigham and Women's Hospital
ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer
The First Affiliated Hospital of Xiamen University
Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk Stratification and Post-Treatment Surveillance in Fresh Thyroid Cancer Patients
National Taiwan University Hospital
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University